FOR IMMEDIATE RELEASE
October 18, 2007
(Carlsbad, California) Invitrogen Corporation (NASDAQ:IVGN),
a provider of essential life science technologies for research,
production and diagnostics, has reached a key milestone in
its agreement with Blue Heron Biotechnology and is now the
co-exclusive worldwide distributor with Blue Heron for its
custom gene synthesis services.
Blue Heron Biotechnology's proprietary GeneMaker® platform can
synthesize gene sequences with perfect accuracy which makes
it ideal for researchers studying anything from single genes
up to entire genomes as in the biofuels and synthetic biology
markets. Researchers worldwide are increasingly turning to
synthetic genes as a convenient, cost-effective alternative for
traditional cloning. Synthetic genes have allowed pharmaceutical
and biotechnology companies to speed the drug discovery process
by rapidly and accurately synthesizing genes of interest that
are in turn used to produce novel proteins, new vaccines and
diagnostics.
"For decades, researchers have depended on Invitrogen's cloning
platforms and gene collections to advance their gene discovery
and functional genomics experiments. With new technologies that
allow the economical production of synthetic genes, researchers
can expand the possibilities of science," said Dr. Balwant
Patel, business area manager for Cloning and Protein Expression
at Invitrogen. "Our relationship with Blue Heron means that
our customers will explore those possibilities with the best
synthetic genetics technologies and the most highly regarded
cloning and expression platforms available commercially."
"This relationship creates unique opportunities to serve the
needs of the research community. We are very enthusiastic about
bringing Blue Heron's technological leadership in gene synthesis
to Invitrogen's unmatched worldwide customer base," said John
Fess, CEO of Blue Heron.
For more information please visit www.invitrogen.com.
About Invitrogen Corporation
Invitrogen Corporation (Nasdaq:IVGN) provides products
and services that support academic and government
research institutions and pharmaceutical and biotech
companies worldwide in their efforts to improve the human
condition. The company provides essential life science
technologies for disease research, drug discovery, and
commercial bioproduction. Invitrogen's own research and
development efforts are focused on breakthrough innovation in
all major areas of biological discovery including functional
genomics, proteomics, bioinformatics and cell biology --
placing Invitrogen's products in nearly every major laboratory
in the world. Founded in 1987, Invitrogen is headquartered
in Carlsbad, California, and conducts business in more than
70 countries around the world.
The company is celebrating 20 years of accelerating scientific
discovery. Invitrogen globally employs approximately 4,300
scientists and other professionals and had revenues of more
than $1.15 billion in 2006. For more information, visit
www.invitrogen.com.
About Blue Heron Biotechnology
Blue Heron Biotechnology is a pioneer and leader in the gene
synthesis market, producing nearly ten million base pairs
of DNA since its inception in 1999. Blue Heron Bio regularly
produces simple to complex DNA sequences from less than 100
base pairs to over 20,000 base pairs, serving hundreds of life
science researchers including 17 of the 20 top pharmaceutical
and biotechnology companies in the world. Blue Heron Bio's
proprietary GeneMaker® technology provides customers access
to complex DNA sequences that are difficult or impossible to
synthesize with other companies' standard processes. Customers
choose Blue Heron for their unmatched customer service, the
strength of their technology and their record of success. For
more information, visit
www.blueheronbio.com.
Safe Harbor Statement
Certain statements contained in this press release are
considered "forward-looking statements" withthe meaning of
the Private Securities Litigation Reform Act of 1995, and it
is Invitrogen's intent that such statements be protected by
the safe harbor created thereby. Forward-looking statements
include, but are not limited to 1) researchers worldwide
are increasingly turning to synthetic genes as a convenient,
cost-effective alternative for traditional cloning; 2) with new
technologies that allow the economical production of synthetic
genes, researchers can expand the possibilities of science; 3)
our customers will explore those possibilities with the best
synthetic genetics technologies and the most highly regarded
cloning and expression platforms available commercially; 4) this
relationship creates unique opportunities to serve the needs
of the research community. Potential risks and uncertainties
include, but are not limited to, a) GeneMaker® platform may
or may not synthesize gene sequences with perfect accuracy; the
risks that the market will not accept the companies products
and services, or that the companies will be unsuccessful in
their efforts to develop new products and services, as well
as other risks and uncertainties detailed from time to time in
Invitrogen's Securities and Exchange Commission filings.
Media Contacts
Revelle Anderson, Invitrogen Corporation, (760) 268-7482,
revelle.anderson@invitrogen.com
Or
Porter Novelli Life Sciences
Jennifer MacArthur, (617) 897-8258,
jmacarthur@pnlifesciences.com
Or
Blue Heron Biotechnology:
Dorene Farnham, (425) 368-4034,
farnham@blueheronbio.com
|
